Payment overview · 2025
General Payments
$675.15
34 reported records · 18 companies
Healthcare provider profile · identity verified
Sally Oliver, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · SEBRING, FL · NPI 1164894317
Verified facts
What the public records show
CMS Open Payments records show Sally Oliver, ARNP received $675.15 in general payments during 2025 across 34 reported records.
PFIZER INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.50 | 16.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $104.46 | 15.5% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.26 | 10.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.17 | 8.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.82 | 6.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.98 | 5.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $37.83 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.15 | 4.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.08 | 4.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.58 | 3.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.74 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.82 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.12 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.61 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.40 | 2.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $13.93 | 2.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $675.15 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $104.46 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.26 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 120 |
| Alprazolam | Alprazolam | 328 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 70 |
| Losartan Potassium | Losartan Potassium | 188 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 70 |
| Lisinopril | Lisinopril | 165 | 54 |
| Gabapentin | Gabapentin | 152 | 65 |
| Tramadol Hcl | Tramadol Hcl | 150 | 40 |
| Omeprazole | Omeprazole | 148 | 56 |
| Furosemide | Furosemide | 123 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 40 |
| Simvastatin | Simvastatin | 111 | 44 |
| Metformin Hcl | Metformin Hcl | 109 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 35 |
| Meloxicam | Meloxicam | 106 | 35 |
| Sertraline Hcl | Sertraline Hcl | 104 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 33 |
| Methylprednisolone | Methylprednisolone | 83 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 37 |
| Trazodone Hcl | Trazodone Hcl | 77 | 29 |
| Azithromycin | Azithromycin | 76 | 68 |
| Montelukast Sodium | Montelukast Sodium | 70 | 24 |
| Lorazepam | Lorazepam | 65 | 14 |
| Atenolol | Atenolol | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 22 |
| Alendronate Sodium | Alendronate Sodium | 57 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 23 |
| Carvedilol | Carvedilol | 53 | 19 |
| Temazepam | Temazepam | 52 | 12 |
| Famotidine | Famotidine | 50 | 19 |
| Glimepiride | Glimepiride | 49 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 22 |
| Eliquis | Apixaban | 48 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 16 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 17 |
| Clonazepam | Clonazepam | 45 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 29 |
| Ezetimibe | Ezetimibe | 38 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Synthroid | Levothyroxine Sodium | 38 | 16 |
| Estradiol | Estradiol | 36 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Glipizide | Glipizide | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 12 |
| Baclofen | Baclofen | 28 | 11 |
| Ozempic | Semaglutide | 28 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 20 |
| Topiramate | Topiramate | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 14 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Finasteride | Finasteride | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Prednisone | Prednisone | 18 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $675.15 · 34 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, CREON, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, QUTENZA, REXULTI, SMARTVEST, TRELEGY ELLIPTA, Tymlos, UBRELVY, XYOSTED, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error